Alto Neuroscience, Inc. (ANRO) Stock Price & Analysis
Alto Neuroscience, Inc. (ANRO) rose 15.95% to USD 21.15 as of June 9, 2026 at 23:34 UTC, according to Nexqual real-time market data.
ANRO last closed at USD 18.24; the session ranged USD 17.97–21.27 on volume of 597,831 shares. Market capitalization is $742.24M, with a 52-week range of USD 2.15–28.44 (NYQ). Source: Nexqual, June 9, 2026 at 23:34 UTC.
Key Statistics (as of June 9, 2026 at 23:34 UTC)
| Price | USD 21.15 |
|---|---|
| Change | ▲ 15.95% (up) |
| Previous Close | USD 18.24 |
| Open | USD 18.46 |
| Day Range | USD 17.97 – 21.27 |
| 52-Week Range | USD 2.15 – 28.44 |
| Volume | 597,831 shares |
| Market Cap | $742.24M |
| Exchange | NYQ |
Technical Analysis (ANRO)
Nexqual's technical model rates ANRO "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:34 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 46.66 (neutral) |
| vs SMA50 | Below (USD 22.96) |
| MACD | -1.12 (negative) |
Analyst Ratings (ANRO)
Wall Street analysts rate ANRO "Strong Buy" based on 11 analysts, with a mean price target of USD 35.13 (range USD 24–50), per Nexqual as of June 9, 2026 at 23:34 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 35.13 |
| High Target | USD 50 |
| Low Target | USD 24 |
| Buy / Hold / Sell | 11 / 1 / 0 |
Earnings (ANRO)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.77 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.8 vs est -0.51 ▼ miss |
| 2025-12-31 | USD -0.45 vs est -0.51 ▲ beat |
| 2025-09-30 | USD -0.52 vs est -0.64 ▲ beat |
| 2025-06-30 | USD -0.65 vs est -0.6 ▼ miss |
Source: Nexqual, June 9, 2026 at 23:34 UTC.
Financials & Fundamentals (ANRO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -38.86% |
| Debt / Equity | 9 |
| Current Ratio | 20.52 |
| Total Cash | $263.76M |
| Total Debt | $21.91M |
| Free Cash Flow | $-39.92M |
Source: Nexqual, June 9, 2026 at 23:34 UTC.
Financial Health Score (ANRO)
Nexqual rates Alto Neuroscience, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:34 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $264M cash vs $22M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$62M |
| Efficiency | Critical — ROE -39%, ROA -21.7% |
Ownership (ANRO)
| Insider Ownership | +4.55% |
|---|---|
| Institutional Ownership | +82.05% |
| Shares Outstanding | 35.09M |
| Float | 23.95M |
| Short % of Float | +5.49% |
Source: Nexqual, June 9, 2026 at 23:34 UTC.
Leadership (ANRO)
Alto Neuroscience, Inc. is led by Amit Etkin (age 48), Founder, Chairman of the Board, CEO & President, per Nexqual as of June 9, 2026 at 23:34 UTC.
| Founder, Chairman of the Board, CEO & President | Amit Etkin (age 48) |
|---|---|
| CFO & Chief Business Officer | Nicholas C. Smith (age 36) |
| Chief Operating Officer | Michael C. Hanley (age 51) |
Major Backers & Investors (ANRO)
Notable institutional backers of Alto Neuroscience, Inc. include Alpha Wave Global, LP, Commodore Capital Lp, Vestal Point Capital, LP, according to Nexqual as of June 9, 2026 at 23:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Alpha Wave Global, LP | 10.57% |
| Commodore Capital Lp | 7.76% |
| Vestal Point Capital, LP | 5.88% |
| Perceptive Advisors Llc | 5.73% |
| Spruce Street Capital LP | 3.78% |
| Franklin Resources, Inc. | 3.14% |
| Vivo Capital, LLC | 2.95% |
| Armistice Capital, LLC | 2.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.8% |
Source: Nexqual, June 9, 2026 at 23:34 UTC.
From Alto Neuroscience, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
- The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYTX | Kyverna Therapeutics, Inc. | USD 7.85 | ▲ 5.09% |
| AVBP | ArriVent BioPharma, Inc. | USD 30.55 | ▲ 0.66% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 7.27 | ▲ 6.13% |
| GUTS | Fractyl Health, Inc. | USD 0.66 | ▼ 2.21% |
| CGON | CG Oncology, Inc. | USD 56.67 | ▲ 5.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:34 UTC. This page is informational and not investment advice.